| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | mpt51 |
| Uniprot No | P9WQN6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-299aa |
| 氨基酸序列 | AEPTAKAAPYENLMVPSPSMGRDIPVAFLAGGPHAVYLLDAFNAGPDVSNWVTAGNAMNTLAGKGISVVAPAGGAYSMYTNWEQDGSKQWDTFLSAELPDWLAANRGLAPGGHAAVGAAQGGYGAMALAAFHPDRFGFAGSMSGFLYPSNTTTNGAIAAGMQQFGGVDTNGMWGAPQLGRWKWHDPWVHASLLAQNNTRVWVWSPTNPGASDPAAMIGQAAEAMGNSRMFYNQYRSVGGHNGHFDFPASGDNGWGSWAPQLGAMSGDIVGAIR |
| 预测分子量 | 44.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MPT51重组蛋白的3篇参考文献概览：
---
1. **文献名称**: *"Cloning, expression, and purification of Mycobacterium tuberculosis MPT51 antigen in Escherichia coli"*
**作者**: Kumar, P. et al.
**摘要**: 该研究成功在大肠杆菌中克隆并表达了重组MPT51蛋白，优化了纯化条件，并通过Western blot验证其抗原性，为结核病血清学诊断提供了候选抗原。
---
2. **文献名称**: *"Structural and functional characterization of the MPT51 protein from Mycobacterium tuberculosis"*
**作者**: Sasaki, Y. et al.
**摘要**: 通过X射线晶体学解析了重组MPT51的三维结构，发现其具有独特的β-折叠结构域，可能参与宿主免疫逃逸，为疫苗设计提供结构基础。
---
3. **文献名称**: *"Evaluation of recombinant MPT51 as a diagnostic marker for tuberculosis"*
**作者**: Li, H. et al.
**摘要**: 评估重组MPT51在结核病患者血清中的抗体反应，显示其敏感性和特异性优于传统抗原，提示其作为血清学诊断标志物的潜力。
---
(注：以上文献信息为示例，实际引用需根据具体论文内容调整。)
**Background of MPT51 Recombinant Protein**
MPT51 (also known as Rv3803c) is a secreted antigenic protein produced by *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB). It belongs to the family of immunogenic secretory proteins that play potential roles in bacterial virulence and host-pathogen interactions. With a molecular weight of approximately 27 kDa, MPT51 is encoded by the *mpt51* gene and is recognized for its immunomodulatory properties, contributing to *M. tuberculosis* immune evasion mechanisms. Studies suggest it may interact with host immune cells, modulating cytokine responses or influencing antigen presentation pathways.
Recombinant MPT51 is produced through genetic engineering, typically by cloning the *mpt51* gene into expression systems like *Escherichia coli*, followed by purification. This recombinant form retains the antigenic and structural features of the native protein, making it valuable for immunological studies. Its immunogenicity has sparked interest in TB diagnosis and vaccine development. For instance, MPT51 has been evaluated as a candidate antigen in serodiagnostic assays to detect TB-specific antibodies, though its sensitivity and specificity vary across populations.
Structurally, MPT51 contains conserved domains characteristic of bacterial fibronectin-binding proteins, including β-strand-rich regions and α-helical motifs. These features may facilitate interactions with host extracellular matrix components or immune receptors. Additionally, MPT51 exhibits cross-reactivity with antibodies against other mycobacterial proteins (e.g., MPT63), complicating its diagnostic utility but highlighting its evolutionary conservation.
Recent research explores MPT51’s role in subunit vaccines, often combined with other antigens like ESAT-6 or Ag85B, to enhance protective immune responses. Preclinical studies indicate that recombinant MPT51 can induce Th1-type immunity, critical for combating intracellular pathogens like *M. tuberculosis*. However, challenges remain in optimizing its efficacy and minimizing cross-reactivity. Overall, MPT51 recombinant protein serves as a tool for understanding TB pathogenesis and advancing therapeutic or preventive strategies against this global health threat.
×
